Zhuang Yifu, Gan Yaokai, Shi Dingwei, Zhao Jie, Tang Tingting, Dai Kerong
Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Sci Rep. 2017 Nov 13;7(1):15463. doi: 10.1038/s41598-017-15451-0.
Bone defects are a common challenge in clinic, usually warranting bone grafts. However, current strategies to obtain effective graft materials have many drawbacks. Mesenchymal stem cell (MSC)-based therapy is a promising alternative. We designed an innovative appliance named the stem cell screen-enrich-combine(-biomaterials) circulating system (SECCS). In this study, 42 patients who required bone graft underwent SECCS-based treatment. Their bone marrow samples and beta-tricalcium phosphate (β-TCP) granules were processed in the SECCS for 10-15 minutes, to produce MSC/β-TCP composites. These composites were grafted back into bone defect sites. The results showed 85.53% ± 7.95% autologous MSCs were successfully screened, enriched, and seeded on the β-TCP scaffolds synchronously. The cell viability remained unchanged after SECCS processing. Clinically, all patients obtained satisfactory bone healing. Thus, without in vitro culture, the SECCS can produce bioactive MSC/β-TCP composites for bone regeneration during surgery. The SECCS represents a convenient, rapid, low-cost, and safe method for bone regeneration.
骨缺损是临床上常见的挑战，通常需要进行骨移植。然而，目前获取有效移植材料的策略存在诸多缺点。基于间充质干细胞（MSC）的治疗是一种有前景的替代方法。我们设计了一种名为干细胞筛选-富集-结合（-生物材料）循环系统（SECCS）的创新装置。在本研究中，42名需要骨移植的患者接受了基于SECCS的治疗。他们的骨髓样本和β-磷酸三钙（β-TCP）颗粒在SECCS中处理10-15分钟，以制备MSC/β-TCP复合材料。这些复合材料被移植回骨缺损部位。结果显示，85.53%±7.95%的自体间充质干细胞被成功筛选、富集并同步接种到β-TCP支架上。经过SECCS处理后，细胞活力保持不变。临床上，所有患者均获得了满意的骨愈合。因此，无需体外培养，SECCS就能在手术过程中生产用于骨再生的生物活性MSC/β-TCP复合材料。SECCS是一种方便、快速、低成本且安全的骨再生方法。
